Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jo Vandercappellen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cytokine & Growth Factor Reviews|November 30, 2010
The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancerJo Vandercappellen, Jo Van Damme, Sofie Struyf
Cancer Letters|June 27, 2008
The role of CXC chemokines and their receptors in cancerJo Vandercappellen, Jo Van Damme, Sofie Struyf
Neurology and Therapy|June 23, 2023
Measuring Fatigue in Multiple Sclerosis: There may be Trouble AheadJames Close, Jo Vandercappellen, Miriam King, et al.
Neurology and Therapy|June 10, 2022
Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease ProcessesTanuja Chitnis, Jo Vandercappellen, Miriam King, et al.
Journal of Clinical Medicine|August 12, 2022
MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis ProgressionTjalf Ziemssen, Jo Vandercappellen, Valeria Jordan Mondragon, et al.
Multiple Sclerosis and Related Disorders|June 16, 2023
Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selectionJeremy Hobart, Tanuja Chitnis, Jiwon Oh, et al.
Blood|March 17, 2007
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migrationPaul Proost, Anneleen Mortier, Tamara Loos, et al.
European Journal of Immunology|February 19, 2009
Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effectsSofie Struyf, Paul Proost, Jo Vandercappellen, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 27, 2022
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?Trishna Bharadia, Jo Vandercappellen, Tanuja Chitnis, et al.
Molecular Cancer Research : MCR|March 11, 2010
The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivoJo Vandercappellen, Sandra Liekens, Annelies Bronckaers, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cytokine & Growth Factor Reviews|November 30, 2010
The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancerJo Vandercappellen, Jo Van Damme, Sofie Struyf
Cancer Letters|June 27, 2008
The role of CXC chemokines and their receptors in cancerJo Vandercappellen, Jo Van Damme, Sofie Struyf
Neurology and Therapy|June 23, 2023
Measuring Fatigue in Multiple Sclerosis: There may be Trouble AheadJames Close, Jo Vandercappellen, Miriam King, et al.
Neurology and Therapy|June 10, 2022
Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease ProcessesTanuja Chitnis, Jo Vandercappellen, Miriam King, et al.
Journal of Clinical Medicine|August 12, 2022
MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis ProgressionTjalf Ziemssen, Jo Vandercappellen, Valeria Jordan Mondragon, et al.
Multiple Sclerosis and Related Disorders|June 16, 2023
Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selectionJeremy Hobart, Tanuja Chitnis, Jiwon Oh, et al.
Blood|March 17, 2007
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migrationPaul Proost, Anneleen Mortier, Tamara Loos, et al.
European Journal of Immunology|February 19, 2009
Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effectsSofie Struyf, Paul Proost, Jo Vandercappellen, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 27, 2022
Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?Trishna Bharadia, Jo Vandercappellen, Tanuja Chitnis, et al.
Molecular Cancer Research : MCR|March 11, 2010
The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivoJo Vandercappellen, Sandra Liekens, Annelies Bronckaers, et al.
Pageof 2